Drug Trial Radar · NCT07381803
The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction
Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,804
Planned (sponsor's estimate)
Start
Jan 27, 2025
Primary completion
Dec 2026
Study completion Jun 2027
Sponsor
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is o evaluate the prognostic effect of fexofenadine hydrochloride in patients with myocardial infarction
Conditions
- Zhejiang University
Interventions
Fexofenadine 60 Mg Oral TabletDrug
Fexofenadine, 60mg BID oral
PlaceboDrug
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major adverse cardiovascular and cerebrovascular events (MACCE)Time frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Zhejiang University, School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.